Skip to main content
Fig. 3 | Antimicrobial Resistance & Infection Control

Fig. 3

From: Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients

Fig. 3

Example therapeutic pathway to determine antimicrobial selection based on phenotypic or genotypic carbapenemase testing while awaiting cascade susceptibility testing results for novel agents (e.g., ceftolozane/tazobactam or ceftazidime/avibactam) based on data in Fig. 2. Implementation can guide selection in the ICU and non-ICU setting

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us